Bristol-Myers Squibb Co vs Ishares Msci Spain ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.44 (market cap $116.30B), while Ishares Msci Spain ETF trades at $59.39. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Ishares Msci Spain ETF pays none, and Ishares Msci Spain ETF is trading nearer its 52-week high, Bristol-Myers Squibb Co nearer its low. Which is the better fit depends on your goals.
| BMY | EWP | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $62.37 | $60.28 |
52-Week Low | $42.60 | $43.48 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
EWP is trading at $58.94, down 0.86% over the past 24 hours. The technical outlook is bullish, with moving averages signaling strength, while oscillators remain neutral. A dividend of $0.92 is scheduled for payment on June 18, 2026. Recent news highlights European market dynamics, including ECB rate hikes and regional economic performance, which may influence this US-listed stock's sentiment.
The stock's outlook is supported by bullish technical signals, but fundamental data is unavailable, limiting valuation assessment. Key risks include reliance on European economic conditions and potential volatility from monetary policy shifts. Investor sentiment appears mixed, with technical strength offset by a lack of recent fundamental catalysts.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →